ISM6166 / Insilico Medicine - LARVOL DELTA

Insilico Medicine…announced the nomination of ISM6166 as a Preclinical Candidate (PCC), a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumors, including lung, pancreatic, colorectal, and gastric cancers, generated and optimized using its Chemistry42 platform (Insilico Medicine Press Release) - "In preclinical studies, ISM6166 demonstrated exceptional anti-tumor efficacy. In lung cancer model, oral administration of ISM6166 achieved 86.2% tumor growth inhibition (TGI) and 55.1% tumor regression at 10 mg/kg and 30 mg/kg, respectively. The anti-tumor efficacy was even more pronounced in gastric cancer model, where a 5 mg/kg dose reached 99.5% TGI, and higher doses induced up to 65.8% tumor regression....Insilico is advancing IND-enabling studies for ISM6166 and aims to bring this potential best-in-class candidate into the clinic."

Pipeline update • Preclinical • Colorectal Cancer • Gastric Cancer • Lung Cancer • Pancreatic Cancer • Solid Tumor